Dr. Reddy’s Announces The Launch Of Montelukast Sodium Tablets And Montelukast Sodium Chewable Tablets

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Montelukast Sodium Tablets (10 mg) and Montelukast Sodium Chewable Tablets (4 mg & 5 mg), bioequivalent generic versions of SINGULAIR® Tablets and Chewable tablets, in the US market on August 6, 2012 following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy’s ANDA.

The SINGULAIR® tablets and Chewable tablets brand had U.S. sales of approximately $3.6 Billion and $1.14 Billion respectively for the most recent twelve months ending March 2012 according to IMS Health.

Dr. Reddy’s Montelukast Sodium Tablets in 10 mg and Montelukast Sodium Chewable Tablets in 4 mg and 5 mg are available in bottle counts of 30 and 90.

Disclaimer

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy’s

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to: www.drreddys.com

SINGULAIR® tablets and chewable tablets are a registered trademark of Merck & Co., Inc.

IMS National Sales Perspectives: Retail and Non-Retail MAT March 2012

If you liked this article you might like

Generics Drop Across Board as DOJ Inquiry Expands

Teva Divests More Assets to Win EC Approval for Allergan Generics Deal

Changing Landscape for Generic-Drug Makers Creates Opportunities

Dr Reddy's Laboratories (RDY) Highlighted As Weak On High Volume

Ex-Dividend Alert: 3 Stocks Going Ex-Dividend Tomorrow: GLV, GLO, RDY